Clinical usefulness of 18F–FDG PET/CT for initial staging and assessment of treatment efficacy in patients with lymph node tuberculosis

Nuclear Medicine and Biology

Volumn 50, Issue , 2017, Pages 17-24

  Lefebvre, Nicolas ^a   Argemi, Xavier ^a   Meyer, Nicolas ^a   Mootien, Joy ^b   Douiri, Nawal ^a   Sferrazza Mandala, Stefania ^a   Schramm, Frédéric ^a   Weingertner, Noëlle ^a   Christmann, Daniel ^a   Hansmann, Yves ^a   Imperiale, Alessio ^a  

^a UNIVERSITY HOSPITAL OF STRASBOURG   (France)

^b Munchberg General Hospital   (France)

Author keywords

18F FDG PET CT; Lymph node; Mycobacterium infection; Positron emission tomography; Tuberculosis

Indexed keywords

FLUORODEOXYGLUCOSE F 18; TUBERCULOSTATIC AGENT;

ADULT; ANTIBIOTIC THERAPY; ARTICLE; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE ASSESSMENT; DISEASE COURSE; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMAGE GUIDED BIOPSY; MALE; PATIENT MONITORING; POSITRON EMISSION TOMOGRAPHY-COMPUTED TOMOGRAPHY; RETROSPECTIVE STUDY; TREATMENT OUTCOME; TREATMENT RESPONSE; TUBERCULOUS LYMPHADENITIS; UNIVERSITY HOSPITAL; WHOLE BODY PET; DIAGNOSTIC IMAGING; METABOLISM; MIDDLE AGED; TRANSPORT AT THE CELLULAR LEVEL;

ADULT; BIOLOGICAL TRANSPORT; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; MALE; MIDDLE AGED; POSITRON EMISSION TOMOGRAPHY COMPUTED TOMOGRAPHY; RETROSPECTIVE STUDIES; TUBERCULOSIS, LYMPH NODE;

EID: 85017547535     PISSN: 09698051     EISSN: 18729614     Source Type: Journal    
DOI: 10.1016/j.nucmedbio.2017.04.003     Document Type: Article

References (33)

1. [1] Khan, A.D., Magee, E., Grant, G., Centers for Disease Control and Prevention (CDC). Tuberculosis - United States, 1993-2010. MMWR Suppl 62 (2013), 149–154.
2. [2] Peto, H.M., Pratt, R.H., Harrington, T.A., LoBue, P.A., Armstrong, L.R., Epidemiology of extrapulmonary tuberculosis in the United States, 1993-2006. Clin Infect Dis 49 (2009), 1350–1357, 10.1086/605559.
3. [3] Fontanilla, J.-M., Barnes, A., von Reyn, C.F., Current diagnosis and management of peripheral tuberculous lymphadenitis. Clin Infect Dis 53 (2011), 555–562, 10.1093/cid/cir454.
4. [4] Maartens, G., Wilkinson, R.J., Tuberculosis. Lancet Lond Engl 370 (2007), 2030–2043, 10.1016/S0140-6736(07)61262-8.
5. [5] WHO, Treatment of tuberculosis: guidelines for national programmes. 2009, WHO.
6. [6] Haroon, A., Zumla, A., Bomanji, J., Role of fluorine 18 fluorodeoxyglucose positron emission tomography-computed tomography in focal and generalized infectious and inflammatory disorders. Clin Infect Dis 54 (2012), 1333–1341, 10.1093/cid/cis193.
7. [7] Basu, S., Chryssikos, T., Moghadam-Kia, S., Zhuang, H., Torigian, D.A., Alavi, A., Positron emission tomography as a diagnostic tool in infection: present role and future possibilities. Semin Nucl Med 39 (2009), 36–51, 10.1053/j.semnuclmed.2008.08.004.
8. [8] Hashefi, M., Curiel, R., Future and upcoming non-neoplastic applications of PET/CT imaging. Ann N Y Acad Sci 1228 (2011), 167–174, 10.1111/j.1749-6632.2011.06082.x.
9. [9] Braun, J.J., Kessler, R., Constantinesco, A., Imperiale, A., 18F-FDG PET/CT in sarcoidosis management: review and report of 20 cases. Eur J Nucl Med Mol Imaging 35 (2008), 1537–1543, 10.1007/s00259-008-0770-9.
10. [10] Imperiale, A., Riehm, S., Veillon, F., Namer, I.-J., Braun, J.-J., FDG PET coregistered to MRI for diagnosis and monitoring of therapeutic response in aggressive phenotype of sarcoidosis. Eur J Nucl Med Mol Imaging 38 (2011), 983–984, 10.1007/s00259-010-1725-5.
11. [11] Ankrah, A.O., van der Werf, T.S., de Vries, E.F.J., Dierckx, R.A.J.O., Sathekge, M.M., Glaudemans, A.W.J.M., PET/CT imaging of mycobacterium tuberculosis infection. Clin Transl Imaging 4 (2016), 131–144, 10.1007/s40336-016-0164-0.
12. [12] Skoura, E., Zumla, A., Bomanji, J., Imaging in tuberculosis. Int J Infect Dis 32 (2015), 87–93, 10.1016/j.ijid.2014.12.007.
13. [13] Netherland, N.A., Peter, S., Education and imaging. Gastrointestinal: positron emission tomography (PET) in intestinal tuberculosis: masquerading hot spots. J Gastroenterol Hepatol 24 (2009), 1798–1799, 10.1111/j.1440-1746.2009.06092.x.
14. [14] Treglia, G., Taralli, S., Calcagni, M.L., Maggi, F., Giordano, A., Bonomo, L., Is there a role for fluorine 18 fluorodeoxyglucose-positron emission tomography and positron emission tomography/computed tomography in evaluating patients with mycobacteriosis? A systematic review. J Comput Assist Tomogr 35 (2011), 387–393, 10.1097/RCT.0b013e318219f810.
15. [15] Demura, Y., Tsuchida, T., Uesaka, D., Umeda, Y., Morikawa, M., Ameshima, S., et al. Usefulness of 18F-fluorodeoxyglucose positron emission tomography for diagnosing disease activity and monitoring therapeutic response in patients with pulmonary mycobacteriosis. Eur J Nucl Med Mol Imaging 36 (2009), 632–639, 10.1007/s00259-008-1009-5.
16. [16] Park, I.-N., Ryu, J.-S., Shim, T.S., Evaluation of therapeutic response of tuberculoma using F-18 FDG positron emission tomography. Clin Nucl Med 33 (2008), 1–3, 10.1097/RLU.0b013e31815c5128.
17. [17] Sathekge, M., Maes, A., Kgomo, M., Stoltz, A., Pottel, H., Van de Wiele, C., Impact of FDG PET on the management of TBC treatment. A pilot study. Nuklearmedizin 49 (2010), 35–40, 10.3413/nukmed-0270.
18. [18] Sathekge, M., Maes, A., D'Asseler, Y., Vorster, M., Gongxeka, H., Van de Wiele, C., Tuberculous lymphadenitis: FDG PET and CT findings in responsive and nonresponsive disease. Eur J Nucl Med Mol Imaging 39 (2012), 1184–1190, 10.1007/s00259-012-2115-y.
19. [19] Sathekge, M., Maes, A., Kgomo, M., Stoltz, A., Van de Wiele, C., Use of 18F-FDG PET to predict response to first-line tuberculostatics in HIV-associated tuberculosis. J Nucl Med 52 (2011), 880–885, 10.2967/jnumed.110.083709.
20. [20] Prasoon, D., Acid-fast bacilli in fine needle aspiration smears from tuberculous lymph nodes. Where to look for them. Acta Cytol 44 (2000), 297–300.
21. 18F-FDG PET and PET/CT. Curr Opin Pulm Med 20 (2014), 287–293, 10.1097/MCP.0000000000000043.
22. [22] Murata, Y., Kubota, K., Yukihiro, M., Ito, K., Watanabe, H., Shibuya, H., Correlations between 18F-FDG uptake by bone marrow and hematological parameters: measurements by PET/CT. Nucl Med Biol 33 (2006), 999–1004, 10.1016/j.nucmedbio.2006.09.005.
23. [23] Krishnan, N., Robertson, B.D., Thwaites, G., The mechanisms and consequences of the extra-pulmonary dissemination of mycobacterium tuberculosis. Tuberculosis (Edinb) 90 (2010), 361–366, 10.1016/j.tube.2010.08.005.
24. [24] Nam, H.-Y., Kim, S.-J., Kim, I.-J., Kim, B.-S., Pak, K., Kim, K., The clinical implication and prediction of diffuse splenic FDG uptake during cancer surveillance. Clin Nucl Med 35 (2010), 759–763, 10.1097/RLU.0b013e3181ef0905.
25. [25] Glaudemans, A.W.J.M., Signore, A., FDG-PET/CT in infections: the imaging method of choice?. Eur J Nucl Med Mol Imaging 37 (2010), 1986–1991, 10.1007/s00259-010-1587-x.
26. [26] Davis, S.L., Nuermberger, E.L., Um, P.K., Vidal, C., Jedynak, B., Pomper, M.G., et al. Noninvasive pulmonary [18F]-2-fluoro-deoxy-D-glucose positron emission tomography correlates with bactericidal activity of tuberculosis drug treatment. Antimicrob Agents Chemother 53 (2009), 4879–4884, 10.1128/AAC.00789-09.
27. [27] Imperiale, A., Federici, L., Lefebvre, N., Braun, J.-J., Pfumio, F., Kessler, R., et al. F-18 FDG PET/CT as a valuable imaging tool for assessing treatment efficacy in inflammatory and infectious diseases. Clin Nucl Med 35 (2010), 86–90, 10.1097/RLU.0b013e3181c7be8d.
28. [28] Visvikis, D., Hatt, M., Tixier, F., Cheze Le Rest, C., The age of reason for FDG PET image-derived indices. Eur J Nucl Med Mol Imaging 39 (2012), 1670–1672, 10.1007/s00259-012-2239-0.
29. [29] Larson, S.M., Erdi, Y., Akhurst, T., Mazumdar, M., Macapinlac, H.A., Finn, R.D., et al. Tumor treatment response based on visual and quantitative changes in global tumor glycolysis using PET-FDG imaging. The visual response score and the change in total lesion glycolysis. Clin Positron Imaging 2 (1999), 159–171.
30. [30] Kim, I.-J., Lee, J.S., Kim, S.-J., Kim, Y.-K., Jeong, Y.J., Jun, S., et al. Double-phase 18F-FDG PET-CT for determination of pulmonary tuberculoma activity. Eur J Nucl Med Mol Imaging 35 (2008), 808–814, 10.1007/s00259-007-0585-0.
31. [31] Martinez, V., Castilla-Lievre, M.A., Guillet-Caruba, C., Grenier, G., Fior, R., Desarnaud, S., et al. (18)F-FDG PET/CT in tuberculosis: an early non-invasive marker of therapeutic response. Int J Tuberc Lung Dis 16 (2012), 1180–1185, 10.5588/ijtld.12.0010.
32. [32] Buck, A.K., Herrmann, K., Stargardt, T., Dechow, T., Krause, B.J., Schreyögg, J., Economic evaluation of PET and PET/CT in oncology: evidence and methodologic approaches. J Nucl Med 51 (2010), 401–412, 10.2967/jnumed.108.059584.
33. [33] Bashir, H., Shabo, G., Nunan TO, Positron emission tomography scanning is coming to a hospital near you soon!. Clin Med 8 (2008), 134–139.